Genetic Factors on Outcomes of Kidney Transplant Patients With Tacrolimus-based Therapy
Status
Conditions
Details and patient eligibility
About
The purpose of this study is to identify the influence of genetic and clinical factors on the clinical outcomes of kidney transplant patients with tacrolimus (TAC) based immunosuppression in Taiwan.
Full description
Tacrolimus (TAC) is the most important immunosuppressants for maintenance therapy after kidney transplantation. Many genetic and clinical factors had been found to have effect on TAC pharmacokinetics (PK). Whether these factors affect clinical outcomes is still controversial.
In this retrospective study, investigators will review records of kidney transplant patients with TAC based immunosuppression recruited from a previous study (IRB approval number: 201512005RINC) to understand the influence of clinical and genetic factors on their 3-years clinical outcomes, including biopsy-proven acute rejection, patient survival, graft survival and safety issues of kidney transplant patients.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Kidney transplantation
- 20-65 years old
- Receiving tacrolimus-based immunosuppressants
- Were recruited in a previous trial
Exclusion criteria
- Human immunodeficiency virus-positive status
- Retransplantation or multiorgan transplantation
- Non-Asian
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal